iPS Cell Differentiation via Small Molecule Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating induced pluripotent stem (iPS) cells into intestinal epithelial cells are complex, inefficient, and require expensive growth factors, limiting their practical application for pharmacokinetic assays and toxicity tests.
Innovation Solution
A method involving the use of small molecule compounds such as cAMP, MEK1 inhibitors, DNA methyltransferase inhibitors, TGF-β receptor inhibitors, and EGF to differentiate iPS cells into intestinal epithelial cells, which effectively induces expression of drug metabolizing enzymes and transport functions, particularly CYP3A4, and maintains intracellular cAMP levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional differentiation methods using growth factors and cytokines are used, then intestinal epithelial cells can be obtained, but the process becomes complex and expensive
Solution Approach 1:
The patent changes the chemical parameters of the differentiation medium by replacing expensive growth factors and cytokines with small molecule compounds. Specifically, it uses compounds that modulate cAMP levels (such as IBMX, forskolin, 8-Br-cAMP) and inhibitors of specific pathways (MEK1/2 inhibitors, GSK3β inhibitors, Wnt pathway inhibitors) to achieve differentiation. This parameter substitution maintains differentiation efficiency while simplifying the method and reducing costs.
2Measurement precision
If primary small intestinal epithelial cells are used, then accurate pharmacokinetic evaluation is achieved, but cell availability becomes limited
Solution Approach 1:
The patent performs preliminary action by differentiating iPS cells into intestinal epithelial cells before they are needed for pharmacokinetic assays. The differentiated cells are then maintained and stored, allowing on-demand use for various experiments. This preliminary differentiation resolves the availability issue while maintaining the functional characteristics necessary for accurate pharmacokinetic evaluation.
3Adaptability or versatility
If Caco-2 cells are used as a model system, then cell availability is improved, but drug transporter expression accuracy deteriorates
Solution Approach 1:
The patent changes the differentiation parameters by using small molecule compounds that specifically induce the expression of drug transporters and metabolizing enzymes. The use of cAMP-elevating compounds (IBMX, forskolin, 8-Br-cAMP) and pathway inhibitors creates a differentiation environment that mimics in vivo intestinal epithelium more accurately than Caco-2 cells, restoring measurement precision while maintaining cell availability through iPS cell derivation.
4Reliability
If expensive growth factors and cytokines are used in large amounts, then differentiation can be induced, but cost efficiency deteriorates
Solution Approach 1:
The patent replaces expensive, long-shelf-life growth factors and cytokines with small molecule compounds that are cheaper and can be used at lower concentrations. The small molecules (IBMX, forskolin, 8-Br-cAMP, pathway inhibitors) serve as disposable differentiation inducers that achieve the same effect at lower cost, improving quantity efficiency while maintaining differentiation capability.
Data Source
AI summary
An object of the present invention is to provide a novel method which enables convenient preparation of cells exhibiting functions close to that of intestinal epithelial cells of living bodies, and use of the method. The differentiation of induced pluripotent stem cells into intestinal epithelial cells is induced by step of differentiating induced pluripotent stem cells into endoderm-like cells; step of differentiating the endoderm-like cells obtained in step into intestinal stem cell-like cells; and step of differentiating the intestinal stem cell-like cells obtained in step into intestinal epithelial cell-like cells, wherein step includes culture in the presence of a MEK1 inhibitor, a DNA methyltransferase inhibitor, a TGF-β receptor inhibitor, and EGF and under the condition that cAMP is supplied to the cells.